Enoxaparin Dosing
For most clinical scenarios, enoxaparin should be dosed at 1 mg/kg subcutaneously every 12 hours for therapeutic anticoagulation, 40 mg once daily for VTE prophylaxis in hospitalized patients, and dose-reduced to 1 mg/kg once daily (therapeutic) or 30 mg once daily (prophylactic) when creatinine clearance is <30 mL/min. 1, 2
Therapeutic Anticoagulation Dosing
Acute Coronary Syndromes
- Initial therapy: 1 mg/kg subcutaneous every 12 hours 1, 2
- With fibrinolytic therapy in patients <75 years: 30 mg IV bolus, followed in 15 minutes by 1 mg/kg subcutaneous every 12 hours (maximum 100 mg for first 2 doses) 1, 2
- With fibrinolytic therapy in patients ≥75 years: No bolus; 0.75 mg/kg subcutaneous every 12 hours (maximum 75 mg for first 2 doses) 1, 2
- To support PCI: If last subcutaneous dose was 8-12 hours earlier, give 0.3 mg IV; if within 8 hours, no additional dose needed 1, 2
Venous Thromboembolism Treatment
- Standard dosing: 1 mg/kg every 12 hours OR 1.5 mg/kg once daily 3
- Both regimens are equally effective; once-daily dosing may improve adherence
Prophylactic Dosing
Standard Prophylaxis
- Hospitalized medical patients: 40 mg once daily 3
- Surgical patients: 40 mg once daily, starting 2-4 hours preoperatively or 10-12 hours preoperatively 3
- Duration: Continue for hospital stay (medical patients) or at least 7-10 days (surgical patients); consider extended prophylaxis up to 4 weeks for high-risk surgical patients 3
Post-Cesarean Delivery
- Standard dose: 40 mg once daily 4
- Timing after neuraxial anesthesia: May start as early as 4 hours after catheter removal but not earlier than 12 hours after the block was performed 4
Renal Impairment Adjustments
Critical adjustment threshold is CrCl <30 mL/min 1, 2, 5, 6, 5
Severe Renal Impairment (CrCl <30 mL/min)
- Therapeutic dosing: 1 mg/kg subcutaneous once daily (instead of every 12 hours) 1, 2, 5, 6, 5
- Prophylactic dosing: 30 mg once daily (instead of 40 mg) 5, 6, 5
- Rationale: Enoxaparin clearance is reduced by 44% in severe renal impairment, increasing bleeding risk 2-3 fold with standard dosing 5, 6
Moderate Renal Impairment (CrCl 30-60 mL/min)
- Some evidence supports dose reduction, but no formal guideline recommendations exist 5, 6
- Consider monitoring anti-Xa levels in prolonged therapy (>10 days) 7
- Enoxaparin clearance reduced by 31% in this population 5, 6
Important Caveats
- Do not routinely monitor anti-Xa levels in renal impairment; instead use dose adjustments as specified above 8
- Consider switching to unfractionated heparin in severe renal impairment as an alternative 8
- Calculate CrCl using Cockcroft-Gault equation 7
Obesity Dosing
Prophylactic Dosing in Obesity
- BMI 40-49 kg/m²: Consider 40 mg every 12 hours (intermediate dose) 4, 9
- BMI ≥50 kg/m²: Consider weight-based dosing at 0.5 mg/kg every 12 hours 4, 9
- Alternative approach: Fixed dose 40 mg twice daily has shown efficacy 10
The 2020 SMFM guideline specifically recommends intermediate doses (40 mg every 12 hours) for class III obesity (BMI ≥40 kg/m²) 4
Therapeutic Dosing in Obesity
- Use actual body weight for dose calculation (1 mg/kg every 12 hours) 8, 11
- Do not routinely monitor anti-Xa levels 8
- For extreme obesity (weight >190 kg), consider anti-Xa monitoring 7
- Recent evidence suggests doses of 0.75-0.85 mg/kg may achieve therapeutic levels more reliably than standard 1 mg/kg dosing in patients with BMI ≥40 kg/m² 11
Key Obesity Considerations
- Standard 40 mg once daily prophylaxis is often insufficient in BMI ≥40 kg/m² 12
- Median dose of 0.57 mg/kg/day achieved prophylactic anti-Xa levels versus 0.50 mg/kg/day in those who did not 12
- Enoxaparin is hydrophilic with minimal volume of distribution changes in obesity, making weight-based dosing appropriate 11
Special Populations
Elderly Patients (≥75 years)
- With fibrinolysis: Omit IV bolus; use 0.75 mg/kg every 12 hours (max 75 mg for first 2 doses) 1, 2, 13, 14
- Age ≥80 years: May require lower doses to achieve target anti-Xa levels compared to younger patients 15
Underweight Patients (BMI <18.5 kg/m²)
- Consider reduced prophylactic dose of 30 mg once daily 16
- No significant difference in bleeding between 30 mg and 40 mg once daily in critically ill underweight patients 16
Pregnancy and Postpartum
- Prophylaxis: 40 mg once daily (standard dose) 4
- Class III obesity in pregnancy: 40 mg every 12 hours 4
- LMWH is preferred over unfractionated heparin due to better bioavailability, longer half-life, and lower risk of heparin-induced thrombocytopenia 4
Monitoring Recommendations
Anti-Xa monitoring is NOT routinely recommended in the following situations 8:
- Renal dysfunction (use dose adjustments instead)
- Obesity (use actual body weight dosing)
- Standard therapeutic or prophylactic use
Consider anti-Xa monitoring only in:
- Extreme obesity (weight >190 kg) 7
- Severe renal impairment with prolonged use (>10 days) 7
- Pregnancy with extreme obesity 4
Target anti-Xa levels when monitoring:
- Prophylactic: 0.2-0.4 units/mL 12
- Therapeutic: 0.5-1.0 units/mL (for twice-daily dosing, measured 4 hours post-dose) 17
Critical Warnings
- Never switch between enoxaparin and unfractionated heparin during treatment due to increased bleeding risk 13, 14
- Avoid in severe renal impairment with CrCl <30 mL/min unless dose-adjusted 1, 2
- Timing with neuraxial anesthesia: Wait at least 12 hours after block placement before giving prophylactic dose; wait 4 hours after catheter removal 4
- Bariatric surgery: Standard prophylactic dosing (40 mg once daily) appears adequate; higher doses increase bleeding without clear VTE benefit 9, 18